Peripheral blood mononuclear cellular viability and its correlation with long-term pulmonary complications after sulfur mustard exposure

Mirsharif, Ensie Sadat; Shams, J; Falahi, Faramarz; Moghadam, Mohamad Reza Sedighi; Majd, Ali Mohamad Mohseni; Dilmaghanian, Razieh; Ghazanfari, Tooba

doi:10.1016/j.intimp.2019.105814

Cited by 1 publication

(1 citation statement)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Late in the course of the disease, SM exposure (SME) is associated with pulmonary complications (Mustard lung) such as asthma, emphysema, chronic bronchitis, obliterative bronchiolitis syndrome, chronic obstructive pulmonary disease, and tracheobronchomalacia [ [14] , [15] , [16] , [17] , [18] , [19] ]. Other long-term effects of SME include cancer, hematologic, immunological, neuropsychiatric, and reproductive problems [ 12 , [20] , [21] , [22] ]. Patients experience eye and skin complications [ 23 , 24 ] and also social isolation [ 15 ].…”

Section: Introductionmentioning

confidence: 99%

Exposure to sulfur mustard increases the risk for mortality in patients with COVID-19 infection: A cohort study

Kolivand¹,

Fathi

Kheyrati

et al. 2022

The American Journal of Emergency Medicine

View full text Add to dashboard Cite

Objective This study aims to assess the prognosis of inpatients with COVID-19 infection who have a history of sulfur mustard exposure. Methods We started a cohort study in October 2020 and ended in May 2021 on inpatients with COVID-19 infection who had been admitted to university healthcare centers. The analytic sample included 960 inpatients having COVID-19 infection (192 with; and 768 without sulfur mustard exposure). The exposed patients were male war veterans, and the unexposed patients were male individually age-matched people. All patients had a positive RT-PCR test and a positive chest CT for COVID-19. The outcome was death within 28 days of admission, and the predictors were clinical features recorded at patients' bedsides. Results There was a significantly higher prevalence for asthma ( p = 0.026) and pulmonary disease other than asthma ( p < 0.001) in patients with the exposure. Sulfur mustard exposure was associated with increased risk for mortality of COVID-19 [hazard ratio (95% CI) = 1.92 (1.14,3.24), p = 0.013]. Early intubation signified a poor prognosis [hazard = 7.34 (4.65,11.58), p < 0.001]. However, individuals with higher PaO2 [hazard = 0.97 (0.95,0.98), p < 0.001], or people undergoing O2 therapy early upon admission [hazard = 0.58 (0.38,0.89), p = 0.011] showed lower risks for mortality. Individuals with asthma were at higher risk for mortality [hazard = 3.76 (1.69,8.36), p = 0.001]. Conclusion Individuals with COVID-19 infection and sulfur mustard exposure should be considered high-risk patients and that, healthcare settings should be ready to provide critical care for them, including O 2 therapy. They are more likely to have asthma or other pulmonary diseases.

show abstract